2015
April 28, 2015
Spotlight Innovation closes $2.5 Million Financing
Spotlight Innovation Inc. (the “Company”) announces that it has closed on an unsecured convertible promissory note in the gross principal amount of $2,500,000, exclusive of certain fees.
Read more…
April 21, 2015
Spotlight Innovation completes Private Placement Offering of $500,000
Spotlight Innovation Inc. (OTCQB: STLT) announces the completion of a $500,000 private placement offering consisting of shares of common stock and warrants.
Read more…
April 06, 2015
Spotlight Innovation subsidiary Celtic Biotech product EPISORB available to compounding pharmacy industry
Spotlight Innovation Inc. (OTCQB: STLT) announces that the product EPISORB, developed by its subsidiary Celtic Biotech Iowa, Inc., has been registered with the U.S. Food and Drug Administration and has been incorporated into the Pharmacy Benefit Managers (PBM) database referenced by health insurance companies when reimbursing drugs. The product makes use of the attributes of cardiotoxin as a cell penetrating peptide and is intended for distribution through the compounding pharmacy industry.
Read more…
March 17, 2015
Spotlight Innovation enters into purchase agreement with Memcine Pharmaceuticals
Spotlight Innovation Inc. (OTCQB: STLT) announces that Spotlight Innovation Inc. entered into a Purchase Agreement with Coralville, Iowa-based Memcine Pharmaceuticals, Inc. Pursuant to the agreement, Spotlight Innovation will acquire a majority of the outstanding securities of Memcine Pharmaceuticals.
Read more…
March 10, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa licenses promising therapy for Chronic Kidney Disease
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD).
Read more…
January 15, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Read more…
January 6, 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC
Spotlight Innovation Inc. (OTCQB:STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Read more…
2014
December 16, 2014
Spotlight Innovation announces change of Transfer Agent
Spotlight Innovation Inc. (OTCQB:STLT) announces today that effective December 16, 2014, all communications related to shareholder transactions should be directed to VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
Read more…
December 4, 2014
Celtic Biotech Iowa requests reactivation and transfer of National Drug Code registration
Spotlight Innovation Inc. (OTCQB:STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product.
Read more…
October 14, 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals
Spotlight Innovation Inc. (OTCQB:STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex™ vaccine platform technology, which is designed to use the body’s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Read more…
October 1, 2014
Spotlight Innovation Retains Jerry Cirino as Special Advisor
Spotlight Innovation Inc. (OTCQB: STLT) has hired Jerry Cirino as a Special Advisor to provide business development expertise and to advise the Company on strategic opportunities and transactions.
Read more…
September 24, 2014
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program
Spotlight Innovation, Inc. (OTCQB: STLT) announced that it has retained Barwicki Investor Relations, a New York-based investor relations firm, to expand the Company’s strategic investor relations program. Barwicki Investor Relations is providing financial community and media relations, and editorial, consulting and advisory services.
Read more…
August 27, 2014
Spotlight Innovation white paper focuses on evolution of efforts to transform University research into profitable business ventures
Spotlight Innovation, Inc. (OTCQB:STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP).
Read more…
August 5, 2014
Spotlight Innovation signs second Letter of Credit with Denver Savings Bank
Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Read more…
July 02, 2014
Spotlight Innovation, Inc., announces closing of financing
Spotlight Innovation, Inc., (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors, through its equity advisor Catwalk Capital, LLC.
Read more…
June 26, 2014
Spotlight Innovation names Dr. David Hostelley Chief Financial Officer
Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company.
Read more…
June 17, 2014
Spotlight Innovation building relationships with Midwest businesses and people
Cristopher Grunewald, President and CEO of Spotlight Innovation said, “The Midwest is a hotbed of talent and innovation, and it has always been a pillar of our business plan to build relationships with people and institutions in the Midwest. We are pleased that we are making good on this commitment.”
Read more…
June 10, 2014
Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., completes merger with Celtic Biotech Ltd.
Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 4, 2014, Celtic Biotech Iowa, Inc. (a subsidiary of Spotlight Innovation, Inc.) has completed a share exchange agreement with biopharmaceutical company Celtic Biotech Ltd.
Read more…
2013
December, 16, 2013
Spotlight Innovation’s name change, symbol change and reverse split approved by FINRA
Spotlight Innovation, Inc. (“the Company”) (OTCQB:STLT) is pleased to announce that effective December 17, 2013 the Financial Industry Regulatory Authority (“FINRA”) has approved the name change of the company from American Exploration Corp. to Spotlight Innovation, Inc., change of stock symbol to “STLT”, and a 1-500 reverse split of our common stock.
Read more…
December 12, 2013
Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
Spotlight Innovation, Inc. (formerly American Exploration Corporation, AEXP:OTCQB), announced today the completion of a merger with Spotlight Innovation, LLC.
Read more…
